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Background: Acute kidney injury (AKI) in traumatic brain injury (TBI) is
poorly understood and it is unknown if it can be attenuated using erythropoietin
(EPO).
Methods: Pre‐planned analysis of patients included in the EPO‐TBI (ClinicalTrials.-
gov NCT00987454) trial who were randomized to weekly EPO (40 000 units) or
placebo (0.9% sodium chloride) subcutaneously up to three doses or until intensive
care unit (ICU) discharge. Creatinine levels and urinary output (up to 7 days) were
categorized according to the Kidney Disease Improving Global Outcome (KDIGO)
classification. Severity of TBI was categorized with the International Mission for
Prognosis and Analysis of Clinical Trials in TBI.
Results: Of 3348 screened patients, 606 were randomized and 603 were analyzed.
Of these, 82 (14%) patients developed AKI according to KDIGO (60 [10%] with
KDIGO 1, 11 [2%] patients with KDIGO 2, and 11 [2%] patients with KDIGO 3).
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Male gender (hazard ratio [HR] 4.0 95% confidence interval [CI] 1.4‐11.2, P = 0.008)
and severity of TBI (HR 1.3 95% CI 1.1‐1.4, P < 0.001 for each 10% increase in risk
of poor 6 month outcome) predicted time to AKI. KDIGO stage 1 (HR 8.8 95% CI
4.5‐17, P < 0.001), KDIGO stage 2 (HR 13.2 95% CI 3.9‐45.2, P < 0.001) and
KDIGO stage 3 (HR 11.7 95% CI 3.5‐39.7, P < 0.005) predicted time to mortality.
EPO did not influence time to AKI (HR 1.08 95% CI 0.7‐1.67, P = 0.73) or creatinine
levels during ICU stay (P = 0.09).
Conclusions: Acute kidney injury is more common in male patients and those with
severe compared to moderate TBI and appears associated with worse outcome.
EPO does not prevent AKI after TBI.
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1 | INTRODUCTION
Traumatic brain injury (TBI) is a rising global health concern affecting
especially the younger population and results in both high mortality
and, in many cases, lifelong morbidity and considerable treatment
costs.1-3 Severely injured TBI patients require treatment in an inten-
sive care unit (ICU).4 During ICU care, TBI patients are at risk of
developing complications such as various degrees of organ failure.5
One serious complication is acute kidney injury (AKI), which has
been shown to occur in 18%‐36% of trauma patients treated in the
ICU.6,7 Severity of AKI may range from a momentary decrease in uri-
nary output or a slight increase in a creatinine, to complete anuria
and the need for renal replacement therapy.7
Recombinant erythropoietin (EPO) has been shown to have renal
protective effects in experimental studies.8-10 The use EPO for pre-
vention of AKI has been studied in patients undergoing cardiac sur-
gery and following renal transplantation, but thus far the data are
conflicting.11-14 No studies have assessed the effect of EPO on kid-
ney function in patients with trauma.15 Accordingly, we aimed to
assess the incidence and factors increasing the likelihood as well as
survival association of AKI in patients with moderate to severe TBI.
Secondarily, we studied the effect of EPO on kidney function by
comparing the occurrence of AKI using the Kidney Disease Improv-
ing Global Outcome (KDIGO) classification and creatinine levels in
patients treated with either EPO or placebo.
2 | METHODS
The EPO‐TBI study was an international randomized controlled trial
conducted in multiple centers in Australia, New Zealand, Saudi Ara-
bia, France, Finland, Ireland and Germany between 3 May 2010
and 1 November 2014.16 All patients treated in the ICU for moder-
ate or severe TBI were screened for eligibility (Figure S1). Patients
with end‐stage renal failure receiving chronic dialysis were excluded
from the trial. Enrolled patients received either weekly doses of
40 000 IU of subcutaneous epoetin alfa (Eprex Janssen‐Cilag Pty
Ltd, Titusville, NJ, USA) or placebo (0.9% sodium chloride). The ran-
domization process and administration of drug has been described
previously.15 The administration of EPO continued until patients
had received a maximum of three doses, or until the patients was
discharged from the ICU.17,18 A consort checklist for the reporting
of this study is included in the Supplemantary Materials. The EPO‐
AKI sub‐study was a pre‐planned study and the protocol (a part of
the original EPO‐AKI protocol) is included in the Supplementary
Materials.
2.1 | Data collection
A web‐based case record form was used including detailed data on
patient characteristics, injury mechanism, pre‐hospital care and
immediate hospital management.17 Specifically, data enabling the cal-
culation of the International Mission for Prognosis and Analysis of
Clinical Trials in TBI (IMPACT‐TBI) risk for poor 6‐month outcome
was included.19 Trained assessors classified injury severity with
Injury Severity Scores (ISS), Abbreviated Injury Scales (AIS) based on
radiological findings and hospital notes. Serum creatinine was
prospectively recorded daily until ICU discharge and urine output
during the first 7 days.
Editorial comment
Erythropoietin (EPO), as a potent hormone that the body
releases in response to some forms of stress, has been
tested as a potentially protective treatment substance in
different clinical contexts. In this post‐hoc subgroup
analysis from an earlier trial, EPO did not appear to alter
risk for kidney injury in traumatic brain injury patients.
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2.2 | AKI based on the KDIGO classification
Stages of AKI according to KDIGO20 were defined as follows:
Stage 1: A 1.5–1.9 fold increase in creatinine compared to the
creatinine measured on hospital admission, an absolute increase
>26.5 μmol/L over 48 hours or a urinary output of <0.5 mL/kg/
h for 6-12 hours.
Stage 2: A 2.0 to 2.9 fold increase in creatinine compared to the
creatinine measured hospital admission or a urinary output
<0.5 mL/kg/h for more than 12 hours.
Stage 3: A threefold increase in creatinine compared to creatinine
measured on hospital admission, an increase in creatinine to
more than 353.6 μmol/L, urinary output of <0.3 mL/kg/h for
more than 24 hours, anuria for more than 12 hours or initiation
of renal replacement therapy.
Daily data on creatinine levels were available during the whole
ICU stay and thus, in our primary analysis we used AKI KDIGO
stages defined by changes in creatinine during the whole ICU stay.
We also reported AKI free ICU days up to 21 days. Data on urinary
output according to the KDIGO stages were only available during
the first 7 days of ICU care. Therefore, in a secondary analysis, we
studied early AKI, defined by changes in either creatinine or UO
occurring during the first 7 days in the ICU. Renal recovery was
defined as the absence of any KDIGO stage 1‐3 on the day of ICU
discharge or at day seven. No data on creatinine or urinary output
after ICU discharge are included in the analysis.
2.3 | Study outcomes
The primary outcome of this study was the presence and timing of
KDIGO stages 1‐3 based on creatinine levels during the whole ICU
stay. A secondary outcome was KDIGO stages 1‐3 based on crea-
tinine levels and urinary output during the first 7 days. Patient out-
comes included ICU, hospital and 6‐month survival. Neurological
function at 6 months was determined by an assessor blinded to
treatment group using the Glasgow Outcome Scale extended
(GOSE). The GOSE ranges from 1‐8 with good outcome defined as a
GOSE score of 5‐8.
2.4 | Sample size analysis
Prior to the study initiation it was estimated that the incidence of AKI
(KDIGO 1‐3 compared to no KDIGO class) would be around 9%. Given
this assessment, a trial with 287 patients in each group was estimated
to have an 86% power to detect a change from 9% to 3% with a two
sided P‐value 0.05. The EPO‐TBI trial enrolled 602 patients.
2.5 | Statistical analysis
Categorical data are presented as counts and percentages and are
compared using chi‐square test. Numerical data are presented as
medians and interquartile range (IQR) in parenthesis. Parametric data
is compared with a Student's t test and non‐parametric data with
the Mann‐Whitney U test (two groups) or Kruskal‐Wallis test (more
than two groups). Cox regression analysis was used to assess inde-
pendent predictors of time to development of AKI and patient sur-
vival at 6 months. Covariates included in the analysis of the
development of AKI included factors that had a P <0.1 in the uni-
variate analysis. Covariates included in the mortality analysis
included covariates pre‐specified in our statistical analysis plan and
included age, presence of hypoxia (oxygen saturation <90%) or
hypotension (systolic blood pressure <90 mm Hg), intracranial mass
lesion, abnormal pupils (not equal or not reactive) and geographical
region (Australia and New Zealand, Saudi Arabia or Europe).21 The
presence of KDIGO class was included as a time‐dependent
covariate and thus included transition between KDIGO states.
Kaplan‐Meier curves for patients with AKI and those without were
compared with a log‐rank test. Creatinine levels over time were
compared with a mixed model with a diagonal covariance structure,
including time, treatment (EPO or placebo) and the interaction
between time and treatment. Statistical analysis was performed with
SPSS version 22.0 (IBM Corp. Released 2013, IBM SPSS Statistics
for Windows, Version 22.0; IBM Corp., Armonk, NY, USA) and SAS
version 9.4 (SAS Institute Inc., Cary, NC, USA).
2.6 | Ethical assessment, consent and trial
registration
The EPO‐TBI study was approved by ethical committees at all study
sites. Informed consent was obtained from the patient′s next of kin
or legal representative prior to study inclusion according to local eth-
ical requirement. The trial was registered at ClinicalTrials.gov
(NCT00987454), the Australian and New Zealand Clinical Trials Reg-
istry (ACTRN12609000827235), and European Drug Regulatory
Authorities Clinical Trials (011‐005235‐22).
3 | RESULTS
3.1 | Incidence of AKI during the first 7 days and
ICU stay
A total of 606 patients were included in the EPO‐TBI trial (Figure 1).
Consent was withdrawn in three patients; therefore, this analysis
included a total of 603 patients. During the whole ICU stay, 82
(14%) patients developed AKI based on changes in creatinine (Fig-
ure 1). Sixty patients (10%) had a KDIGO stage of 1, 11 (2%) a
KDIGO stage of 2, and 11 (2%) a KDIGO stage of 3 (Figure 1). Med-
ian time to the highest KDIGO day was 6 days (IQR 4‐9). Of the 82
patients with AKI, 59 (72%) had renal recovery prior to ICU dis-
charge. Eight (1.3%) patients received RRT (seven during ICU stay)
and of these, seven (88%) were alive at 6 months. The median time
to initiation of RRT was 8 days (IQR 5‐11) and in one patient, RRT
was initiated on the day of ICU admission. During the first 7 days,
210 (35%) patients developed AKI according to UO, 29 (5%)
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according to creatinine changes and 23 (4%) according to both crea-
tinine and UO changes (Figure S1).
3.2 | Admission risk factors for AKI
There were several differences in both patient, injury and treat-
ment characteristics between patients that developed and those
who did not develop AKI during ICU stay (Table S1). Notably,
patients with AKI were more commonly of male gender; had a
higher body weight and more severe brain injury (Table S1). On
Cox regression analysis, independent predictors of time to devel-
opment of AKI were male gender (HR 4.0 95% CI 1.4‐11.2,
P = 0.008), and severity of TBI according to the IMPACT model
(per 10% increase in risk of poor outcome, HR 1.25 95% CI 1.1‐
1.4, P < 0.001; Table 1).
3.3 | Risk factors for AKI on day 3
In a COX regression model for time to AKI later than day 3, exclud-




   2645 did not meet inclusion citeria
          694 had traumac brain injury > 48h ago
          535 outside eligible range
          203 death expected<24h
          166 GCS score of 3 and dilated pupils
          95 spinal cord injury
          93 haemoglobin level higher than allowed
          2 due to chronic renal disease and dialysis
          857 due to other reasons
606 randomised
3 withdrew consent, 1 had missing creanine data
521 no kidney injury
259 treated with placebo
262 treated with erythropoien
82 acute kidney injury
39 treated with placebo
43 treated with etrythropoien
60 KDIGO 1
28 treated with placebo
32 treated with erythropoien
11 KDIGO 2
6 treated with placebo
5 treated with erythropoien
11 KDIGO 3
5 treated with placebo
6 treated with erythropoien
F IGURE 1 Flowchart of patients included in the EPO‐TBI trial and the development of various stages of acute kidney injury based on
changes in creatinine during ICU stay. EPO, erythropoietin; ICU, intensive care unit; TBI, traumatic brain injury
TABLE 1 Multivariable analysis of admission factors related to development of time to acute kidney injury in patients with traumatic brain
injury (TBI) included in the erythropoietin (EPO) in TBI trial
Variable Univariate HR (95% CI) P‐value Multivariate HR (95% CI P‐value
Patient weight 1.01 (1.001‐1.02) 0.03 1.01 (0.99‐1.02) 0.32
Male gender 3.99 (1.46‐10.89) 0.007 4.02 (1.44‐11.23) 0.008
Injury mechanism:
Motorcycle accident 1.67 (0.94‐2.97) 0.08 1.72 (0.95‐3.11) 0.07
Pedestrian accident 1.44 (0.78‐2.66) 0.24 1.67 (0.89‐3.13) 0.11
TBI severity according to IMPACT risk of poor outcome (per 10%) 1.19 (1.07‐1.33) 0.002 1.24 (1.10‐1.40) <0.001
APACHE II score 1.01 (0.98‐1.04) 0.47 0.99 (0.96‐1.03) 0.56
IMPACT, International Mission for Prognosis and Analysis of Clinical Trials.
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factors were identified; Male gender (HR 7.2 95% CI 1.7‐29.9,
P = 0.007), TBI severity (per 10% increase in risk of poor outcome
HR 1.2 95% CI 1.1‐1.4, P = 0.007), and the use of therapeutic
hypothermia on days 1‐2 (HR 2.6 95% CI 1.5‐4.5, P = 0.001) were
independently associated with time to development of AKI after day
3. The use of EPO was not associated with time to AKI (HR 0.9 95%
CI 0.6‐1.5, P = 0.70) (Table S2).
3.4 | Association of AKI with outcome
Patients with AKI (any KDIGO stage 1‐3 during their ICU stay) had a
higher ICU mortality (32% compared to 6%, P < 0.001), hospital
mortality (33% compared to 8%, P < 0.001) and 6‐month mortality
(34% compared to 10%, P < 0.001; Table S3). Prior to day 3, 26
patients had died and nine patients had developed AKI. Survival
curves of patients who had developed AKI and where alive at day 3
are shown in Figure 2. Median stay in the ICU was longer in patients
with AKI (15 IQR 8‐25) compared to those without AKI (12 IQR 7‐
20; P = 0.005). However, median hospital length of stay was not dif-
ferent between patients with AKI (28 IQR 11‐49) and those without
(25 IQR 15‐43; P = 0.91; Table S3). Similar findings were seen in
patients with AKI occurring during the first 7 days (Table S4). Good
neurologic recovery defined according to the GOSE scale occurred
in 31 (38%) of 82 AKI patients compared to 299 (58%) of 514 non‐
AKI patients (P < 0.001).
In a Cox regression model including KDIGO class as a time‐
dependent covariate, all three KDIGO stages were related to
6‐month mortality (Table 2). Other significant predictors of increased
mortality were age (HR 1.04 95% CI 1.02‐1.05, P < 0.001), abnormal
pupils (HR 2.0 95% CI 1.2‐3.3, P = 0.01) while treatment with EPO
(HR 0.61 95% CI 0.38‐0.96, P = 0.03) predicted decreased mortality.
Similar findings were seen using AKI occurring during the first 7 days
(Table S5).
3.5 | Effect of EPO on AKI
The cumulative number of patients with AKI treated with EPO and
placebo in the study and over time in the ICU are shown in Fig-
ures 1, 3 and S1. In Cox regression analysis, the use of EPO was not
found to influence time to development of AKI during the whole
ICU stay (HR 0.99 95% CI 0.96‐1.03, P = 0.56) or during the first
7 days (HR 1.01 95% CI 0.79‐1.28, P = 0.96). Creatinine levels over
time are shown in Figure S3. There were no differences in creatinine
values over time in patients treated with EPO compared to placebo
(P = 0.09) nor were there any interactions between intervention
(EPO or placebo) with time (P = 0.99). There was no difference in
AKI free days between EPO treated patients (median 11 days, IQR
5‐18) compared to placebo treated patients (median 11, IQR 5‐19;
P = 0.95).
4 | DISCUSSION
We studied the EPO‐TBI trial population to assess the incidence and
outcome associations of AKI in patients with TBI admitted to ICU.
Moreover, we aimed to test whether EPO treatment was associated
with any evidence of a renal protective effect. We found that AKI as
defined by the KDIGO criteria based on creatinine levels occurred in
one in seven patients. AKI based on either urinary output or crea-
tinine levels during the first 7 days was more common and occurred
in 40% of patients. All forms of AKI had an independent association
with long‐term mortality, but the CIs were wide. Finally, the use of
EPO did not provide any protection from AKI.
The incidence of AKI was comparable to previous studies con-
ducted in patients with trauma and TBI. Eriksson et al reported the
development of AKI in 103 (25%) patients in a sample of 413 ICU
patients admitted following trauma. In a large study involving reg-
istry data of trauma patients admitted to the ICU7, Bagshaw et al6
reported an AKI incidence rate of 18% during the first 24 hours.
Gomes et al22 observed AKI in 50% of trauma patients admitted to
the ICU. Noteworthy is that this study, due to its design, excluded
some categories of patients in whom AKI might be even more
common.
All stages of AKI were associated with a marked increase in mor-
tality compared to patients without AKI. Previous studies including
patients with all types of trauma, have shown similar findings, but
data in patients with TBI have are limited.6,7,23,24 One possible
mechanism for the increase in mortality in TBI is aggravated cerebral
edema due to changes in osmolality.26 In a recent study, Siew et al26
showed that among ICU patients with shock and respiratory failure,
KDIGO stage 2 and 3 are significant risk factors for both delirium
and coma. Interestingly, the use of RRT has been shown to be asso-
ciated with a very high mortality after TBI.26 This was not the case
in this study, as all but one of eight patients that received RRT
survived.
This study identified several known markers of increased risk of
AKI including male gender. This observation may be explained by
F IGURE 2 Survival curves in 599 (excluding deaths prior to day
3) traumatic brain injury patients treated in the intensive care unit
indexed by the development of acute kidney injury before day 3
based on creatinine and urinary output [Colour figure can be viewed
at wileyonlinelibrary.com]
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differences in weight and muscle mass between males and females:
a greater increase in creatinine in males may occur without a true
decrease in renal function. This study also suggested an association
between the use of therapeutic hypothermia (TH) and increased like-
lihood of AKI. It is possible that vasoconstriction, induced by
hypothermia, reduces renal blood flow.27 A meta‐analysis including
mainly patients resuscitated from cardiac arrest suggested no differ-
ence in the prevalence of AKI in between TH and normothermia.28
On the other hand in a sub‐study from the Hypothermia and Cardiac
Arrest trial, the use of hypothermia was associated with a delay in
renal recovery.29 The study on the use of early induction of TH in
TBI by Clifton et al30 showed no difference in creatinine levels
between groups but did show an increased use of intravenous fluids
with TH.
Despite multiple animal studies suggesting positive effects on
the kidney, we did not find that EPO protected patients from AKI.31
The use of EPO in animal models has been shown to decrease the
extent of ischemia reperfusion injury, reduce the incidence of con-
trast induced nephropathy and alleviate inflammation.8-10,32 The pro-
posed protective mechanisms include reduction in apoptotic cell
TABLE 2 Independent predictors of mortality in patients included in the erythropoietin (EPO) in traumatic brain injury (TBI) trial including
time to development and severity of acute kidney injury
Variable Univariate HR (95% CI) P‐value Multivariate HR (95% CI P‐value
Age 1.03 (1.02‐1.05) <0.001 1.04 (1.02‐1.05) <0.001
Hypotension 1.15 (0.72‐1.84) 0.52 1.06 (0.65‐1.75) 0.81
Hypoxia 1.31 (0.78‐2.23) 0.31 1.44 (0.83‐2.5) 0.20
No intracranial mass lesion 0.72 (0.43‐1.23) 0.23 0.77 (0.45‐1.3) 0.33
Pupils abnormal (not equal, non‐reactive) 2.20 (1.37‐3.52) 0.001 2.00 (1.21‐3.3) 0.01
Region (Saudi Arabia reference)
Australia and New Zealand 0.82 (0.53‐1.28) 0.39 0.71 (0.22‐2.32) 0.30
Europe 1.05 (0.63‐1.77) 0.84 0.57 (0.16‐2.00)
Moderate TBI 0.7 (0.4‐1.22) 0.21 0.68 (0.38‐1.2) 0.19
Acute kidney injurya
KDIGO 1 8.61 (4.52‐16.42) <0.001 8.76 (4.51‐16.99) <0.001
KDIGO 2 14.24 (4.36‐46.56) <0.001 13.22 (3.87‐45.16)
KDIGO 3 8.61 (2.7‐27.48) <0.001 11.72 (3.46‐39.68)
Treatment with EPO 0.65 (0.41‐1.02) 0.06 0.61 (0.38‐0.96) 0.03
KDIGO, Kidney Disease Improving Global Outcome.
aThe reference category is no AKI (Absence of KDIGO 1‐3).
F IGURE 3 The timing and cumulative cases of acute kidney in injury in patients treated with erythropoietin (EPO) or placebo in the EPO in
traumatic brain injury trial [Colour figure can be viewed at wileyonlinelibrary.com]
SKRIFVARS ET AL. | 205
death by several mechanisms.33,34 In the ischemic kindey EPO
enhances tissue regeneration, and neovascularization.35,36 EPO also
suppresses the synthesis of TNF‐alpha and interleukin‐2 inflamma-
tory markers which may part in the development of AKI.34 In smaller
clinical trials, EPO has been shown to alleviate early AKI after coro-
nary artery bypass grafting.37 Thus, in trauma patients EPO could
the expected to have some protective effects within 24‐48 hours
after injury. Despite experimental and evidence, a lack in positive
effects on renal function has been shown in patients undergoing kid-
ney transplantation and in this study, in TBI patients with trauma.15
It needs to be noted that the renal endpoints we studied, that is,
KDIGO although relevant, may be too crude to detect smaller
changes in renal function. All in all our finding corroborate that
human AKI is much more complex than in experimental AKI.
4.1 | Study strengths and limitations
This study has a number of strengths. Centres from different health
systems participated and therefore our results are likely to be gener-
alizable. We also had detailed data on severity of TBI and were able
to adjust for that in the analysis.
Nonetheless several limitations need to be kept in mind. The
study did not include data specific medical conditions such as hyper-
tension, diabetes mellitus or chronic kidney disease that may influ-
ence the development of AKI. In addition, the study did not include
data on the use of medications, maintenance fluids, myoglobin levels,
or therapies that might have influenced renal function. We only had
data on urinary output during the first 7 days. The UO data only
included whether any of the KDIGO UO criteria occurred during the
first 7 days and did not include hourly or total diuresis. The study
only includes short‐term data on kidney function and thus we cannot
comment of long‐term effects of EPO on kidney function. Finally, as
the main sample size calculation was based on an assumed change
in neurologically intact survivors at 6 months between the EPO and
placebo groups, this sub‐study may be underpowered to detect clini-
cally meaningful differences the more severe forms of AKI such as
the need for RRT in TBI patients.
5 | CONCLUSION
Within this RCT including patients with moderate to severe TBI, AKI
was independently associated with mortality. We identified several
factors associated with increasing the risk of AKI including increasing
patient weight, male gender, more severe TBI, more severe admis-
sion illness severity, and the use of therapeutic hypothermia. Con-
trary to our hypothesis and despite compelling animal evidence, the
use of EPO did not attenuate renal injury in this population.
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